ABSTRACT

Conclusion:

It is concluded that, protein-tyrosine kinase inhibitor imatinib may cause dose related degenerative changes in the liver, and liver functions should be monitored in patients during treatment.

Results:

In 10 mg/kg and 50 mg/kg imatinib applied experimental groups, the nuclear and cytoplasmic structures, sinusoidal and perisinusoidal areas were similar to the control group. In 100 mg/kg imatinib applied group cytoplasmic density was increased, lytic areas and lipid accumulation in cytoplasm of some hepatocytes were seen. In 200 mg/kg imatinib applied experimental group lytic changes and lipid accumulation were prominent.

Methods:

200-250 g, 8-12 weeks old, 30 mature male Wistar rats were used. Rats were divided in 5 groups; 10, 50, 100 and 200 mg/kg imatinib daily were administered by gavage during 21 days to the experimental groups respectively. Fifth group was control; saline was given. Serum levels of liver transaminases, bilirubin, alkaline phosphatase were examined, morphological effects were investigated via electron microscopy.

Aim:

Imatinib is a protein tyrosine kinase inhibitor that’s used as an anticancer drug. In this study, evaluation the effects of different doses of imatinib on liver ultrastructurally and biochemically was aimed.

References

1Capdeville R, Silberman S, Dimitrijevic S. Imatinib: the first 3 years. Eur J Cancer 2002;38:77-82.

2Lyseng-Williamson K, Jarvis B. Imatinib. Drugs 2001;61:1765-74.

3Agrawal M, Garg RJ, Cortes J, Quintás-Cardama A. Tyrosine kinase inhibitors: the first decade. Curr Hematol Malig Rep 2010;5:70-80.

4Moen MD, McKeage K, Plosker GL, Siddiqui MA. Imatinib: a review of its use in chronic myeloid leukaemia. Drugs 2007;67:299-320.

5Hsiao HH, Liu YC, Tsai HJ, et al. Imatinib mesylate therapy in advanced gastrointestinal stromal tumors: experience from a single institute. Kaohsiung J Med Sci 2006;22:599-603.

6An JY, Choi MG, Noh JH, et al. Gastric GIST: a single institutional retrospective experience with surgical treatment for primary disease. Eur J Surg Oncol 2007;33:1030-5.

7Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-6.

8Wang S, Wilkes MC, Leof EB, Hirschberg R. Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. FASEB J 2005;19:1-11.

9Schellings MW, Baumann M, van Leeuwen RE, et al. Imatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2)27 rats. Hypertension 2006;47:467-74.

10Yoshiji H, Noguchi R, Kuriyama S, et al. Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. Am J Physiol Gastrointest Liver Physiol 2005;288:907-13.

11Gonzalo T, Beljaars L, van de Bovenkamp M, et al. Local inhibition of liver fibrosis by specific delivery of a platelet-derived growth factor kinase inhibitor to hepatic stellate cells. J Pharmacol Exp Ther 2007;321:856-65.

12Guilhot F. Indications for imatinib mesylate therapy and clinical management. Oncologist 2004;9:271-81.

13Kansu E. Hedeflenmiş tedavilerde “hedef” moleküller. Available from: https://www.kanser.org/saglik/upload/Hedefe_Yonelik_Tedavi_KUrsu/Hedeflenmi%c5%9f_Tedavilerde_Hedef_Molek%c3%bcller%23Emin_Kansu.pdf ANKEM Derg 2005;19(Ek 2):112-6.

14Erdogan A, Özkan A. Moleküler hedefli anti-kanser ajan kombinasyonlarını optimize etmek için stratejiler. Archives Medical Review Journal 2015;24:432-51.

15Üskent N. Hedefe yönelik tedaviler ne kadar isabetli? Onkoloji Bülteni Onkovital 2010;4:1. DOI: 10.17827/aktd.55888

16Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene 2000;19:5548-57.

17Di Gion P, Kanefendt F, Lindauer A, et al. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Clin Pharmacokinet 2011;50:551-603.

18Mucke H. The role of imatinib in the treatment of pulmonary hypertension. Drugs Today (Barc) 2013;49:203-11.

19Jang SW, Ihm SH, Choo EH, et al. Imatinib mesylate attenuates myocardial remodeling through inhibition of platelet-derived growth factor and transforming growth factor activation in a rat model of hypertension. Hypertension 2014;63:1228-34.

20Wu TT, Goodarzi H, Wang J, Novoa R, Teng JMC. Imatinib as a potentially effective therapeutic alternative in corticosteroid-resistant eosinophilic fasciitis. Pediatr Dermatol 2020;37:1171-2.

21Cross TJ, Bagot C, Portmann B, Wendon J, Gillett D. Imatinib mesylate as a cause of acute liver failure. Am J Hematol 2006;81:189-92.

22Garcia-Cortes M, Robles-Diaz M, Stephens C, Ortega-Alonso A, Lucena MI, Andrade RJ. Drug induced liver injury: an update. Arch Toxicol 2020;94:3381-407.

23Mihajlovic M, Ivkovic B, Jancic-Stojanovic B, et al. Modulation of oxidative stress/antioxidative defence in human serum treated by four different tyrosine kinase inhibitors. Anticancer Drugs 2020;31:942-9.

24Boyer-Diaz Z, Morata P, Aristu-Zabalza P, Gibert-Ramos A, Bosch J, Gracia-Sancho J. Oxidative Stress in Chronic Liver Disease and Portal Hypertension: Potential of DHA as Nutraceutical. Nutrients 2020;12:2627.

25Ferrero D, Pogliani EM, Rege-Cambrin G, et al. Corticosteroids can reverse severe imatinib-induced hepatotoxicity. Haematologica 2006 ;91:27.

Effects of Imatinib on Rat Liver

ABSTRACT

References